Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
This suggests that SIRT7 may be a potential target for therapeutic intervention aimed at preserving cognitive function in the elderly 102
ResMed CEO: Big Pharma is squarely focused on GLP-1 medications right now Image courtesy of ResMed ResMed CEO Mick Farrells stance on the issue is that the latest advances in both Big Tech and Big Pharma can potentially bring incredible numbers of new patients into the healthcare system where ResMed is uniquely positioned to provide ongoing care at home. Patients are voting with their wallets and respiratory therapists and physicians are voting with their recommendations and their prescriptions. During the companys first-quarter earnings call, Farrell said the company is laser-focused on growing the market to help people get on the therapy they need and on a pathway to better sleep, better health, and better long-term care
What you need to know about the compounded GLP-1 ban If youve been using semaglutide (found in Ozempic and Wegovy) or tirzepatide (Zepbound or Mounjaro) to manage your blood sugar or weight, youve likely heard about new changes in how these medications are made and sold
Based on a retrospective study of self-reported data of 387 participants comparing active versus passive users who were offered the Noom program when being prescribed an early GLP-1
Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases
